ClinicalTrials.Veeva

Menu

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

Pfizer logo

Pfizer

Status and phase

Completed
Phase 1

Conditions

HCV

Treatments

Drug: [14C]-PF-00868554

Study type

Interventional

Funder types

Industry

Identifiers

NCT00823745
A8121013

Details and patient eligibility

About

This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C] PF-00868554 and to characterize the metabolic profile following single dose administration.

Enrollment

7 patients

Sex

Male

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male, healthy volunteers.

Exclusion criteria

  • Females.

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

7 participants in 1 patient group

1
Experimental group
Description:
\[14C\]-PF-00868554
Treatment:
Drug: [14C]-PF-00868554

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems